Marlene Hennessy
Principal Scientist Exelixis, Inc.
Marlene Hennessy is a Principal Scientist at Exelixis with more than 15 years of experience in preclinical oncology and drug discovery research. Her expertise spans immuno-oncology, translational pharmacology, in vivo model development, mechanism-of-action studies, and the preclinical evaluation of novel cancer therapeutics. At Exelixis, she contributes to the advancement of next-generation oncology programs, including ADCs, supporting the design and characterization of innovative targeted therapies. Prior to joining Exelixis, Marlene held scientific positions at Nektar Therapeutics and Roche, where she worked across multiple therapeutic areas including oncology, inflammation, pain, and autoimmune diseases. She is recognized for her deep expertise in preclinical pharmacology and translational cancer research.
Seminars
- Evaluating rationale for targeting DLL3 with an ADC, laying out selective overexpression in SCLC and neuroendocrine cancers
- Describing design and development of XB773 highlighting humanized VHH Fc antibody conjugated to Topo1 payload via AJICAP conjugation
- Laying out preclinical characterization across in vitro cytotoxicity and internalization and in vivo efficacy in CDX and PDX models
